Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
Contents
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
## Reference and Administrative Details
Chief Executive Officer
Trustees
Principal Office
Registered Office
Company Registration Number Charity Registration Number
Independent Examiner
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
## Trustees' Report
## Our Mission
## Our Vision
## Public Benefit
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
## Trustees' Report
## Objectives and activities
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
## Trustees' Report
Review of activities
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
## Trustees' Report
## Fundraising disclosures
## Charity Funds Expenditure
## Research
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
## Trustees' Report
## Research Grants Awarded
## Financial review
## Policy on reserves
## Plans for future periods
Aims and key objectives for future periods
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
## Trustees' Report
## Going concern
## Structure, governance and management
Recruitment and appointment of trustees
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
## Trustees' Report
## Organisational structure
## Key Involvement
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
## Trustees' Report
## Statement of Trustees' Responsibilities
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
## Independent Examiner's Report to the trustees of Melanoma UK Limited
## Respective responsibilities of trustees and examiner
## Basis of independent examiner’s report
Independent examiner's statement
03-Mar-2026
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
Statement of Financial Activities for the Year Ended 31 August 2025 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)
Unrestricted Restricted Total funds funds 2025 Note £ £ £
Income and Endowments from:
**----- Start of picture text -----**
Expenditure on:
**----- End of picture text -----**
**----- Start of picture text -----**
Reconciliation of funds
**----- End of picture text -----**
**----- Start of picture text -----**
Unrestricted Restricted Total
funds funds 2024
Note £ £ £
**----- End of picture text -----**
Income and Endowments from:
Expenditure on:
**----- Start of picture text -----**
Reconciliation of funds
**----- End of picture text -----**
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
## (Registration number: 8180701) Balance Sheet as at 31 August 2025
**----- Start of picture text -----**
2025 2024
Note £ £
**----- End of picture text -----**
## Fixed assets
## Current assets
Creditors: Amounts falling due within one year Net current assets Net assets Funds of the charity: Restricted funds
Unrestricted income funds
## Total funds
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
## Notes to the Financial Statements for the Year Ended 31 August 2025
## 1 Charity status
## 2 Accounting policies
Summary of significant accounting policies and key accounting estimates
## Statement of compliance
## Basis of preparation
## Going concern
## Exemption from preparing a cash flow statement
## Income and endowments
## Donations and legacies
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
## Notes to the Financial Statements for the Year Ended 31 August 2025
## Investment income
## Expenditure
## Charitable activities
## Support costs
## Governance costs
## Taxation
## Tangible fixed assets
## Depreciation and amortisation
## Asset class
Depreciation method and rate
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
Notes to the Financial Statements for the Year Ended 31 August 2025
## Stock
## Cash and cash equivalents
## Trade creditors
## Fund structure
Financial instruments
Classification
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
## Notes to the Financial Statements for the Year Ended 31 August 2025
## Recognition and measurement
## 3 Income from donations and legacies
**----- Start of picture text -----**
Unrestricted
funds
Total Total
General 2025 2024
£ £ £
181,674 181,674
6,159 6,159
187,833 187,833
Unrestricted
funds
Total Total
General 2025 2024
£ £ £
**----- End of picture text -----**
4 Income from other trading activities
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
Notes to the Financial Statements for the Year Ended 31 August 2025
- 5 Investment income
- 6 Expenditure on charitable activities
**----- Start of picture text -----**
Unrestricted
funds
Total Total
General 2025 2024
£ £ £
6,064 6,064
Unrestricted
funds
Total Total
General 2025 2024
Note £ £ £
8 79,659 79,659
114,655 114,655
7 9,490 9,490
203,804 203,804
Activity Total Total
support costs 2025 2024
£ £ £
**----- End of picture text -----**
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
Notes to the Financial Statements for the Year Ended 31 August 2025
||Activity|Total|Total|
|---|---|---|---|
||support costs|2025|2024|
||£|£|£|
|Governance|9,490|9,490|13,940|
||203,804|203,804|241,113|
|£203,804 (2024 - £241,113) of the above expenditure was|attributable to unrestricted funds and £Nil (2024|||
|£Nil) to restricted funds.||||
|7
Analysis of governance and support costs||||
|Governance costs||||
||Unrestricted|||
||funds|||
|||Total|Total|
||General|2025|2024|
||£|£|£|
|Independent examiner fees||||
|Examination ofthe financial statements|3,300|3,300|3,300|
|Other fees paid to examiners|6,190|6,190|10,639|
||9,490|9,490|13,939|
|8
Staff costs||||
|The aggregate payroll costs were as follows:||||
|||2025|2024|
|||£|£|
|Staff costs during the year were:||||
|Wages and salaries||78,333|22,508|
|Pension costs||1,326||
|||79,659|22,883|
|The monthly average number ofpersons (including senior|management team) employed by the Charity during|||
|the year expressed as full time equivalents was as follows:||||
|||2025|2024|
|||No|No|
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
**----- Start of picture text -----**
Notes to the Financial Statements for the Year Ended 31 August 2025
9 Independent examiner's remuneration
2025 2024
£ £
Examination of the financial statements 3,300
Other fees to examiners
All other services 6,190
10 Taxation
The Charity is a registered charity and is exempt from taxation of its income and gains falling within section
of the Income Tax Act 2007 to the extent that they are applied to its charitable objectives. No tax charge
arisen in the current and prior year.
11 Tangible fixed assets
Furniture and
equipment Total
£ £
Cost
At 1 September 3,170
Additions 80
At 31 August 2025 3,250
Depreciation
At 1 September 202 380
Charge for the year 652
At 31 August 2025 1,032
Net book value
At 31 August 2025 2,218
At 31 August 2024 2,790
12 Stock
2025 2024
£ £
Stocks 13,374
13 Debtors
2025 2024
£ £
**----- End of picture text -----**
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
## Notes to the Financial Statements for the Year Ended 31 August 2025
|14 Creditors: amounts falling due within one year|Creditors: amounts falling due within one year|||||
|---|---|---|---|---|---|
||||2025|2024||
||||£|£||
|Trade creditors|||21,999|25,752||
|Other taxation and social security|||274||(947)|
|Other creditors|||307||-|
|Accruals|||5,490||6,940|
||||28,070|31,745||
|15 Funds||||||
||Balance at 1|||||
||September|Incoming|Resources|Balance at 31|Balance at 31|
||2024|resources|expended|August 2025|August 2025|
||£|£|£|£||
|Unrestricted funds||||||
|General||||||
|General|306,091|211,758|(203,804)|314,045||
|Restricted funds||||||
|NonMelanoma Skin Cancer|1,000|-|-||1,000|
|B-rafAwareness|3,562|-|-||3,562|
|Total restricted funds|4,562|-|-||4,562|
|Total funds|310,653|211,758|(203,804)|318,607||
||Balance at 1|||||
||September|Incoming|Resources|Balance at 31|Balance at 31|
||2023|resources|expended|August 2024|August 2024|
||£|£|£|£||
|Unrestricted funds||||||
|General||||||
|General|261,260|285,944|(241,113)|306,091||
|Restricted funds||||||
|NonMelanoma Skin Cancer|1,000|-|-||1,000|
|B-rafAwareness|3,562|-|-||3,562|
|Total restricted funds|4,562|-|-||4,562|
|Total funds|265,822|285,944|(241,113)|310,653|310,653|
Docusign Envelope ID: F2001828-76C5-4C2C-AA2A-D763D6F0FB2F
## Melanoma UK Limited
## Notes to the Financial Statements for the Year Ended 31 August 2025
16 Analysis of net assets between funds
Unrestricted funds Restricted General funds Total funds £ £ £